APA (7th ed.) Citation

Garon, E. B., Scagliotti, G. V., Gautschi, O., Reck, M., Thomas, M., Docampo, L. I., . . . Pérol, M. (2020). Exploratory analysis of front-line therapies in REVEL: A randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO open, 5(1), . https://doi.org/10.1136/esmoopen-2019-000567

Chicago Style (17th ed.) Citation

Garon, Edward B., et al. "Exploratory Analysis of Front-line Therapies in REVEL: A Randomised Phase 3 Study of Ramucirumab Plus Docetaxel Versus Docetaxel for the Treatment of Stage IV Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy." ESMO Open 5, no. 1 (2020). https://doi.org/10.1136/esmoopen-2019-000567.

MLA (9th ed.) Citation

Garon, Edward B., et al. "Exploratory Analysis of Front-line Therapies in REVEL: A Randomised Phase 3 Study of Ramucirumab Plus Docetaxel Versus Docetaxel for the Treatment of Stage IV Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy." ESMO Open, vol. 5, no. 1, 2020, https://doi.org/10.1136/esmoopen-2019-000567.